GeneDx Lowers Core Testing Growth Target To At Least 17% — But Keeps Sales Forecast
Third-quarter sales rose 5%, while adjusted earnings fell to $8.6 million from $16.1 million a year earlier.
GeneDx, which uses genetic testing to help doctors diagnose rare diseases, cut its full-year exome and genome revenue growth target Monday to at least 17% from at least 20%, according to its SEC filing and accompanying results. The company kept its overall sales forecast of $475 million to $490 million, even as it lowered expectations for core testing volumes.
More Tests, Less Quarterly Profit
GeneDx's unaudited third-quarter sales rose 5% from a year earlier to $123.1 million. Exome and genome testing brought in $110.4 million, up 12%, with 32,134 test results delivered—25% more than a year earlier. Samples received for testing increased 28%.
Those gains did not translate into higher year-over-year earnings. Adjusted net income fell to $8.6 million from $16.1 million, though it improved by $8.2 million from the second quarter. The standard-accounting loss widened to $12.3 million from $7.635 million; loss per share increased to $0.41 from $0.27.
Adjusted gross margin was 72%, below the year-earlier 74% but above the second quarter's 70%. Standard-accounting gross margin was 70%. Adjusted operating expenses totaled $79.4 million, equal to 65% of revenue, while standard-accounting operating expenses were $96.5 million.
Other testing panels generated $9.7 million, down from $14.6 million a year earlier. Their test volume fell to 26,524 from 34,514.
A Lower Bar For Core Growth
Management now expects full-year exome and genome test volume to grow at least 28%, rather than at least 30%. It also raised its forecast for adjusted gross margin to approximately 71% from approximately 70%, and put expected adjusted net income at approximately $12 million, replacing its earlier forecast of a positive result.
The reduced growth targets still describe an expanding business. GeneDx's earnings presentation puts third-quarter 2024 core testing revenue at $60.0 million, with 19,262 tests. In 2026, core revenue progressed from $90.6 million in the first quarter to $100.3 million in the second and $110.4 million in the third.
GeneDx CEO Katherine Stueland said, "Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale."
Turning Coverage Into Payment
GeneDx's ExomeDx and GenomeDx tests examine protein-coding DNA or the entire genome for disease-causing genetic changes. Diagnostic test reports accounted for substantially all 2025 revenue, with payments coming from insurers, patients, business clients and healthcare partners.
Coverage and collections are separate measures of that business. The earnings presentation says 82% of third-quarter outpatient genome volume was submitted to insurers with a positive coverage policy, while the outpatient genome collection rate was 36%. Whole-genome Medicaid coverage reached 25 state programs with the addition of Arkansas and Utah.
GeneDx ended September with $171.1 million in cash, cash equivalents, marketable securities and restricted cash. For the fourth quarter, management expects $135 million in sales, including $121 million from exome and genome testing on 34,500 tests.
Management expects fourth-quarter adjusted gross margin of at least 71% and approximately $12 million in adjusted net income—the same earnings amount it now forecasts for the full year.
Sources
- 8-K Filing — GeneDx Holdings Corp. (WGS) — SEC EDGAR
- Exhibit exhibit991-q32026pressrele.htm — GeneDx Holdings Corp. 8-K exhibit — SEC EDGAR
- Exhibit exhibit992q32026earnings.htm — GeneDx Holdings Corp. 8-K exhibit — SEC EDGAR
- GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026 – Company Announcement - FT.com — Financial Times
- GeneDx Reports Third Quarter 2026 Financial Results — businesswire.com